Related Experiment Video
Updated: May 22, 2025
09:34
Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
Published on: April 4, 2018
33.4K
Barriers and facilitators for implementing a pharmacogenetic passport: lessons learned from reusing sequencing data
Anja H A Roelofsen1, Loes Lindiwe Kreeftenberg1,2, Carla G van El1,2
1Department of Human Genetics, Amsterdam UMC, location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Pharmacogenomics
|May 21, 2025
Summary
Implementing a pharmacogenetic passport, which uses genetic data for personalized medicine, faces barriers like data infrastructure and knowledge gaps. Facilitators include efficiency and patient data control, guiding future implementation strategies.
Area of Science:
- Pharmacogenetics and Personalized Medicine
- Health Informatics
- Genomic Data Utilization
Background:
- Pharmacogenetics optimizes drug treatment by analyzing genetic profiles to prevent adverse drug reactions.
- Reusing existing sequencing data for a pharmacogenetic passport offers preemptive, lifelong patient information for healthcare providers.
Purpose of the Study:
- To explore stakeholder perceptions on barriers and facilitators for implementing a pharmacogenetic passport.
- To assess future perspectives on reusing sequencing data for pharmacogenetic passports in a Dutch University Medical Center.
Main Methods:
- Semi-structured interviews were conducted with 21 stakeholders.
- Thematic analysis was used to analyze interview data, with themes categorized under structure, culture, and practice.
Main Results:
- Barriers included inadequate data infrastructure, limited pharmacogenetic knowledge, unclear guidelines and tasks, and competing hospital priorities.
- Facilitators comprised the ease, efficiency, and affordability of obtaining results from reused sequencing data, positive stakeholder attitudes, and patient control over health data.
Conclusions:
- Strategies to overcome barriers and enhance facilitators are crucial for pharmacogenetic passport implementation.
- Focusing on data infrastructure, guideline visibility, task clarity, and pharmacogenetic education is essential.
Related Concept Videos
03:00Next-generation Sequencing
86.7K
The first human genome sequencing project cost $2.7 billion and was declared complete in 2003, after 15 years of international cooperation and collaboration between several research teams and funding agencies. Today, with the advent of next-generation sequencing technologies, the cost and time of sequencing a human genome have dropped over 100 fold.
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features....
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features....
86.7K
01:57Sanger Sequencing
752.0K
DNA sequencing is a fundamental technique that is routinely used in the biological sciences. This method can be applied to a range of questions at different scales - from the sequencing of a cloned DNA fragment or the study of a mutation in a gene up to whole-genome sequencing. However, despite the widespread use of sequencing today, it was not until 1977 that Fredrick Sanger and his collaborators developed the chain-termination method to decode DNA sequences. It relies on the separation of a...
752.0K